Can malondialdehyde be used as a biological marker of progression in neurodegenerative disease?

Journal of Neurology

Volumn 249, Issue 4, 2002, Pages 367-374

  Dib, Michel ^a   Garrel, Catherine ^b   Favier, Alain ^b   Robin, Valérie ^a   Desnuelle, Claude ^c  

^a SANOFI   (France)

^b HÔPITAL MICHALLON   (France)

^c UNIVERSITY HOSPITAL OF NICE   (France)

Author keywords

Alzheimer's disease; Amyotrophic lateral sclerosis; Malondialdehyde; Oxidative stress; Parkinson's disease

Indexed keywords

ALPHA TOCOPHEROL; BIOLOGICAL MARKER; COPPER ZINC SUPEROXIDE DISMUTASE; DOPAMINE; FREE RADICAL; GLUTATHIONE; LEVODOPA; MALONALDEHYDE; RILUZOLE; SELEGILINE;

AGE; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIOXIDANT ACTIVITY; BRAIN LEVEL; BRAIN REGION; CLINICAL TRIAL; DEGENERATIVE DISEASE; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE MARKER; DRUG EFFECT; HUMAN; HUNTINGTON CHOREA; LIPID PEROXIDATION; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ANIMALS; BIOLOGICAL MARKERS; DISEASE PROGRESSION; HUMANS; MALONDIALDEHYDE; NEURODEGENERATIVE DISEASES; OXIDATIVE STRESS;

EID: 0036226623     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004150200025     Document Type: Review

References (128)

1. Upregulation of protein-tyrosine nitration in the anterior horn of cells of amyotrophic lateral sclerosis
2. No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease
3. A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease
4. No evidence for increased oxidative damage to lipids, proteins, or DNA in Huntington's disease
5. Oxidative DNA damage in the parkinsonian brain: An apparent selective increase in 8-hydroxyguanine in the substantia nigra
6. MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer's and Huntington's disease
7. Mitochondrial dysfunction in neurodegenerative diseases
8. Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis
9. The free radical theory of aging matures
10. Lipid peroxidation: A review of causes, consequences, measurement and dietary influences
11. Determination of malonaldehyde in Alzheimer's disease: A comparative study of high-performance liquid chromatography and thiobarbituric test
12. Determination of hydroxyl free radical formation in human platelets using high-performance liquid chromatography with electrochemical detection
13. Superoxide dismutase activity, oxidative damage and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis
14. Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia
15. Oxidative stress in Huntington's disease
16. Elevated oxidative stress in models of normal brain aging and Alzheimer's disease
17. Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease
18. Oxidative stress and Alzheimer disease
19. From Charcot to SOD1: Mechanisms of selective motor neuron death in ALS
20. Oxidative stress, mitochondrial respiration and Parkinson's disease
21. Oxidative stress and motor neurone disease
22. Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis
23. Amyotrophic lateral sclerosis and structural defects in Cu, Zn superoxide dismutase
24. A double-blind, placebo controlled randomised clinical trial of α-tocopherol (vitamin E), in the treatment of amyotrophic lateral sclerosis
25. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease
26. Increased levels of lipid hydroperoxides in parkinsonian substantia nigra: An HPLC and ESR study
27. Lipid peroxidation and nitrite plus nitrate levels in brain tissue from patients with Alzheimer's disease
28. Copper, iron and zinc imbalances in severely degenerated brain regions in Alzheimer's disease: Possible relation to oxidative stress
29. Effects of riluzole on glutaminergic neurotransmission in the mammalian central nervous system and other pharmacological effects
30. The role of excitotoxicity in neurodegenerative disease: Implications for therapy
31. Estimation of peroxidative damage: A critical review
32. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes
33. Induction of nitric oxide-dependent apoptosis in motor neurons by zinc-deficient superoxide dismutase
34. Vitamin E as a universal antioxidant and stabilizer of biological membranes
35. Oxidative stress: Value of its demonstration in medical biology and problems posed by the choice of a marker
36. How to demonstrate the occurence of an oxidative stress in humans?
37. Influence of apolipoprotein E genotype on blood redox status of Alzheimer's disease patients
38. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis
39. Antioxidants, oxidative stress and degenerative neurological disorders
40. Protein nitration in Parkinson's disease
41. Evidence for neuronal oxidative damage in Alzheimer's disease
42. Loss of in vitro metal ion binding specificity in mutant copper-zinc superoxide dismutase associated with familial amyotrophic lateral sclerosis
43. Vitamin E and Alzheimer disease: The basis for additional clinical trials
44. Bioenegetics in Huntington's disease
45. Mutant CuZn superoxide dismutase in motor neuron disease
46. Brain membrane fluidity and lipid peroxidation in Alzheimer's disease
47. Immunocytochemical method for investigating in vivo neuronal oxygen radical-induced lipid peroxidation
48. Evidence against the involvement of reactive oxygen species in the pathogenesis of neuronal death in Down's syndrome and Alzheimer disease
49. A model for B-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: Relevance to Alzheimer disease
50. Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation
51. Oxidative stress indicators are elevated in de novo Parkinson's disease
52. The role of excitotoxicity in neurological disease
53. Oxidative stress and the pathogenesis of Parkinson's disease
54. Do antioxidants in the diet affect the risk of developing Parkinson's disease?
55. Serum antioxidant enzyme activity in Parkinson's disease
56. Roles of lipid peroxidation in modulation of cellular signalling pathways, cell dysfunction and death in the nervous system
57. Iron as a catalyst for oxidative stress in the pathogenesis of Parkinson's disease
58. Increased erythrocyte susceptibility to lipid peroxidation in human Parkinson's disease
59. Assessing the effects of deprenyl on longevity and antioxidant defences in different animal models
60. Dose-ranging study of riluzole in amyotrophic lateral sclerosis
61. Does selegiline modify the progression of early Parkinson's disease? Results from a five-year study
62. The effects of early selegiline therapy on long-term levodopa therapy treatment and parkinsonian disability. An interim analysis of a Norwegian-Danish 5 year study
63. Excitotoxicity in ALS
64. The roles of free radicals in amyotrophic lateral sclerosis: Reactive oxygen species and elevated oxidation of protein, DNA and membrane phospholipids
65. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease
66. Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer's disease
67. An assessment of oxidative damage to proteins, lipids and DNA in brain from patients with Alzheimer's disease
68. B-amyloid-induced toxicity in rat hippocampal cells: In vitro evidence for the involvement of free radicals
69. Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer's disease
70. Oxidative stress hypothesis in Alzheimer's disease
71. The role of oxidative stress in Alzheimer's disease
72. Oxidative alterations in Alzheimer's disease
73. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease
74. Chemistry and biology of DNA damage by malondialdehyde
75. Experimental Parkinson's disease in monkeys. Effect of ergot alkaloid derivative on lipid peroxidation in different brain areas
76. Increased susceptibility of Alzheimer's disease temporal cortex to oxygen free radical-mediated processes
77. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease
78. Efficacy of riluzole in the treatment of amyotrophic lateral sclerosis
79. The role of oxidative stress in the toxicity induced by amyloid beta-peptide in Alzheimer's disease
80. Serum lipid peroxides in patients with Parkinson's disease
81. Distribution of reducible 4-hydroxynonenol adduct immunoreactivity in Alzheimer disease is associated with APOE genotype
82. Measurement of lipid peroxidation
83. Riluzole improves measures of oxidative stress following spinal cord injury
84. Early selegiline therapy reduces levodopa dose requirement in Parkinson's disease
85. Gain in function of mutant Cu, Zn-superoxide dismutases as a causative factor in familial amyotrophic lateral sclerosis: Less reactive oxidant formation but high spontaneous aggregation and precipitation
86. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease
87. Immunohistochemical and ELISA assays for biomarkers of oxidative stress in aging and disease
88. Evaluation of antioxidants, protein and lipid oxidation in blood from sporadic amyotrophic lateral sclerosis patients
89. Oxidative stress and Parkinson's disease
90. Selegiline delays the onset of disability in de novo parkinsonian patients
91. Selective increase in lipid peroxidation in the inferior temporal cortex in Alzheimer's disease
92. Immunohistochemical evidence of antioxidant stress in Alzheimer's disease
93. Striatal oxidative damage parallels the expression of a neurological phenotype in mice transgenic for the mutation of Huntington's disease
94. Oxidative damage in Alzheimer's disease: The metabolic dimension
95. Erythrocyte antioxidant activity in human patients with Parkinson's disease
96. Oxidative damage to mitochondrial DNA in Huntington's disease parietal cortex
97. Oxidative insults are associated with apolipoprotein E genotype in Alzheimer's disease brain
98. Free radicals in Alzheimer's disease
99. Lipid peroxidation, antioxidant protection and aging
100. Oxidative stress in amyotrophic lateral sclerosis
101. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis
102. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease
103. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease
104. Evidence for mitochondrial dysfunction in Parkinson's disease - A critical appraisal
105. Calcium, glutamate and amyotrophic lateral slerosis: More evidence but no certainties
106. Serum and cerebrospinal fluid biochemical markers of ALS
107. DATATOP: A decade of neuroprotective enquiry
108. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease
109. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting the basal ganglia
110. Presence of 4-hydroxynonenal in cerebrospinal fluid of patients with sporadic amyotrophic lateral sclerosis
111. Oxidative damage in Alzheimer's
112. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals
113. Oxidative stress in Alzheimer's disease
114. Evaluation of the pro-oxidant and antioxidant actions of L-DOPA and dopamine in vitro: Implications for Parkinson's disease
115. Dopamine turnover and glutathione oxidation: Implications for Parkinson's disease
116. Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse
117. In Alzheimer's disease, heme oxygenase is coincident with Alz50, an epitope of tau induced by 4-hydroxy-2-nonenal modification
118. 2 neurons, a classical model for Alzheimer's disease, are highly susceptible to oxidative stress
119. Apolipoprotein E allele-dependent antioxidant activity in brains with Alzheimer's disease
120. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease
121. Alterations of 3-nitrotyrosine concentration in the cerebrospinal fluid during aging and in patients with Alzheimer's disease
122. Remarkable increase in cerebrospinal fluid 3-nitrotyrosine in patients with amyotrophic lateral sclerosis
123. The biological significance of malondialdehyde determination in the assessment of tissue oxidative stress
124. High doses of vitamin E in the treatment of disorders of the central nervous system in the aged
125. Altered reactivity of superoxide dismutase in familial amyotrophic lateral sclerosis
126. Glycated tau protein in Alzheimer disease: A mechanism for induction of oxidant stress
127. A familial amyotrophic lateral sclerosis-associated A4V Cu, Zn-superoxide dismutase mutant has a lower Km for hydrogen peroxide
128. A gain-of-function for an amyotrophic lateral sclerosis-associated Cu,Zn-superoxide dismutase mutant: An enhancement of free radical formation due to a decrease in Km for hydrogen peroxide